Evidence map›Paper›PMID 41866411›Full record

Observational studyJournal of gastroenterology2026

Efficacy and safety of peptide radionuclide therapy with

Kohei Okamoto, Susumu Hijioka, Noritoshi Kobayashi, Hiroshi Imaoka, Kazuo Hara, Satoshi Takeuchi, Nao Fujimori, Kentaro Sudo, Shigeru Horiguchi, Ryoji Takada and 32 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

Kohei OkamotoDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan.
Susumu HijiokaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. shijioka@ncc.go.jp.ORCID 0000-0002-0394-6876
Noritoshi KobayashiDepartment of Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Hiroshi ImaokaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kazuo HaraDepartment of Gastroenterology, Aichi Cancer Center, Nagoya, Japan.
Satoshi TakeuchiDepartment of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Nao FujimoriDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kentaro SudoDepartment of Gastroenterology, Chiba Cancer Center, Chiba, Japan.
Shigeru HoriguchiDepartment of Gastroenterology and Hepatology, Okayama University Hospital, Okayama, Japan.
Ryoji TakadaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Takashi OnoDepartment of Radiation Oncology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Takeshi TerashimaDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Kazuhiko ShiojiDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Shunsuke KondoDepartment of Medical Oncology, Tokyo Women's Medical University, Tokyo, Japan.
Takaaki FurukawaDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Masayuki UenoDepartment of Gastroenterology and Hepatology, Kurashiki Central Hospital, Kurashiki, Japan.
Hidetaka TsumuraDepartment of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan.
Kazutoshi TobimatsuDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Toshifumi DoiMolecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hiroyuki AsamaDepartment of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Shinya KawaguchiDepartment of Gastroenterology, Shizuoka General Hospital, Shizuoka, Japan.
Yohei KitanoDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Osamu MaedaDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Satoshi KobayashiDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Shiho ArimaDigestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Michiaki UnnoDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Eizaburo OhnoDepartment of Gastroenterology and Hepatology, Fujita Health University, Aichi, Japan.
Kazuhito KawataHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Reiko AshidaSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Atsushi NaganumaDepartment of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Go MurohisaDepartment of Hepatology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Reiko YamadaDepartment of Gastroenterology and Hepatology, Mie University Hospital, Tsu, Japan.
Hironaga SatakeDepartment of Medical Oncology, Kochi Medical School, Kochi, Japan.
Yuzo KodamaDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Isao YokotaDepartment of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Hiroyuki OkuyamaDepartment of Medical Oncology, Kagawa University Hospital, Miki, Japan.
Satoshi ShimizuDepartment of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
Chigusa MorizaneDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Hiroaki NaganoDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Junji FuruseDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Japan Oncology Network in Hepatobiliary and Pancreas

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeptide receptor radionuclide therapy (PRRT) is an effective treatment for neuroendocrine neoplasms (NENs); however, real-world data in Asia remain limited.

methodsIn this multicenter, nationwide study, we retrospectively analyzed 422 patients with unresectable or recurrent NENs who received

resultsThe median age was 64 years. The most common primary sites were pancreas (n = 210, 54.8%) and hindgut (n = 81, 21.1%), with fewer midgut cases (n = 19, 5.0%). The tumor grades were G1 (13.3%), G2 (71.2%), G3 (14.6%), and neuroendocrine carcinoma (1.8%). The objective response rate (ORR) was 37.6%, favorable in pancreas (45.2%) and hindgut (40.7%). The median progression-free survival (PFS) was 21.4 months (95% confidence interval [CI], 19.7-22.8). Of 24 patients with hormonal symptoms, 18 (75%) showed marked improvement. Multivariate analysis revealed the following predictors: for ORR (odds ratio, 95% CI), pancreas (4.02, 2.18-7.78), hindgut (3.14, 1.53-6.69), Krenning score (KS) of 4 (2.96, 1.54-6.04), and liver metastasis ≤ 30 mm (1.64, 1.01-2.67); for PFS (hazard ratio, 95% CI), Ki-67 < 10% (0.46, 0.32-0.66), KS of 4 (0.65, 0.43-0.99), liver tumor burden < 50% (0.59, 0.39-0.89), liver tumor size ≤ 30 mm (0.49, 0.32-0.74), and combination with somatostatin analogs (0.64, 0.42-0.99). Grade ≥ 3 adverse events were infrequent, including hematologic (18%) and renal toxicities (< 1%).

conclusions

Indexed as

Neuroendocrine TumorsOctreotideOrganometallic CompoundsRadiopharmaceuticalsAdultAgedAged, 80 and overEast Asian PeopleFemaleHumansJapanMaleMiddle AgedPancreatic NeoplasmsProgression-Free SurvivalReceptors, Peptidelutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadiopharmaceuticalsReceptors, Peptide177Lu-DOTATATEJapanese patientsMulticenter studyNeuroendocrine neoplasmPRRT

Identifiers

PMID41866411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.